Overview

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk and non-T2D patients.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
MOUNT SINAI HOSPITAL
Sunnybrook Health Sciences Centre
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin